Large-scale manufacturing of direct-acting antivirals for
hepatitis C is possible within the next 15 years, with a minimum target
price of $100 to $250 for a 12-week treatment course, recent data
At that cost, widespread access to such treatments in low- and
middle-income countries is a feasible goal, according to the research
team from Liverpool University in the United Kingdom, Howard University
in Washington, D.C., Imperial College London and University of Cape Town
in South Africa.